JP2016523953A - 3−[(3−{[4−(4−モルホリニルメチル)−1h−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1h−インドール−5−イル)メチル]−1,3−チアゾリジン−2,4−ジオンの新規塩、その調製及びそれを含有する製剤 - Google Patents
3−[(3−{[4−(4−モルホリニルメチル)−1h−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1h−インドール−5−イル)メチル]−1,3−チアゾリジン−2,4−ジオンの新規塩、その調製及びそれを含有する製剤 Download PDFInfo
- Publication number
- JP2016523953A JP2016523953A JP2016524879A JP2016524879A JP2016523953A JP 2016523953 A JP2016523953 A JP 2016523953A JP 2016524879 A JP2016524879 A JP 2016524879A JP 2016524879 A JP2016524879 A JP 2016524879A JP 2016523953 A JP2016523953 A JP 2016523953A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- methyl
- thiazolidine
- pyrrol
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 title claims description 7
- AREYWCZYVPSHGS-UHFFFAOYSA-N 3-[[3-[[4-(morpholin-4-ylmethyl)-1h-pyrrol-2-yl]methylidene]-2-oxo-1h-indol-5-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1CC1=CC=C(NC(=O)C2=CC=3NC=C(CN4CCOCC4)C=3)C2=C1 AREYWCZYVPSHGS-UHFFFAOYSA-N 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 title description 6
- 238000002360 preparation method Methods 0.000 title description 4
- 238000009472 formulation Methods 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 15
- -1 4-morpholinylmethyl Chemical group 0.000 claims abstract description 13
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 29
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- KOTRJUJOFATJCR-UHFFFAOYSA-N 3-[[4-(morpholin-4-ylmethyl)-1H-pyrrol-2-yl]methylidene]-1H-indol-2-one Chemical compound N1(CCOCC1)CC=1C=C(NC=1)C=C1C(NC2=CC=CC=C12)=O KOTRJUJOFATJCR-UHFFFAOYSA-N 0.000 claims description 4
- 229910002056 binary alloy Inorganic materials 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- FPSAJUOIYZSJJA-UHFFFAOYSA-N 3-[[3-[[4-(morpholin-4-ylmethyl)-1h-pyrrol-2-yl]methylidene]-2-oxo-1h-indol-5-yl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride Chemical compound Cl.O=C1CSC(=O)N1CC1=CC=C(NC(=O)C2=CC=3NC=C(CN4CCOCC4)C=3)C2=C1 FPSAJUOIYZSJJA-UHFFFAOYSA-N 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 231100000024 genotoxic Toxicity 0.000 claims 1
- 230000001738 genotoxic effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- HQLHIJUHHREFEW-UHFFFAOYSA-N methanesulfonic acid;1,3-thiazolidine-2,4-dione Chemical compound CS(O)(=O)=O.O=C1CSC(=O)N1 HQLHIJUHHREFEW-UHFFFAOYSA-N 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HLEPAHCDDMLYAE-UHFFFAOYSA-N methanesulfonic acid 3-[[3-[[4-(morpholin-4-ylmethyl)-1H-pyrrol-2-yl]methylidene]-2-oxo-1H-indol-5-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound CS(O)(=O)=O.O=C1CSC(=O)N1Cc1ccc2NC(=O)C(=Cc3cc(CN4CCOCC4)c[nH]3)c2c1 HLEPAHCDDMLYAE-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
で表される3−[(3−{[4−(4−モルホリニルメチル)−1H−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1H−インドール−5−イル)メチル]−1,3−チアゾリジン−2,4−ジオンの新規塩、その調製プロセス、さらにはそれを含有する医薬組成物に関する。
[式中、表記×は、二重結合がZ又はE配置であることを意味する]
で表される3−[(3−{[4−(4−モルホリニルメチル)−1H−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1H−インドール−5−イル)メチル]−1,3−チアゾリジン−2,4−ジオンメタンスルホン酸塩に関する。
−優れた収率でそれを得るための単純かつ再現性のあるプロセス;
−水と有機溶媒の両方における増加した溶解度(このことは、その純度を高めるために、浄化などの精製段階を想定することができる)。
3−[(3−{[4−(4−モルホリニルメチル)−1H−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1H−インドール−5−イル)メチル]−1,3−チアゾリジン−2,4−ジオン1.26gを100mLのフラスコに投入する。アセトニトリル/水(90/10)の溶液20mLを加えた後、混合物を70℃で加熱する。メタンスルホン酸2mL及びアセトニトリル/水(90/10)混合物50mLを含有する溶液を調製する。得られた溶液5mLを反応混合物に加えると、それは透明になる。溶液を20℃に冷却する(0.5℃/分、200rpmで撹拌する)。周囲温度で一晩撹拌した後、標記生成物を濾過によって単離し、真空下40℃で乾燥させる(10mbar)。
融点:270〜274℃(溶融/分解)
単位格子パラメーター:a=15.0958(5)Å、b=18.4586(6)Å、c=8.8269(2)Å、β=94.074(1)°、γ=90°
空間群:C1c1(9)
単位格子の体積:V単位格子=2453.37600Å3。
単位格子パラメーター:a=14.995(4)Å、b=18.302(4)Å、c=8.850(2)Å、β=93.528(7)°、γ=90°
空間群:C1c1(9)
単位格子の体積:V単位格子=2424.0(9)Å3。
水7ml中の実施例1で得られた化合物140mgを含有する溶液を周囲温度で24時間撹拌する。Acrodisc GHP 0.45μmを使用した濾過後、溶液をHPLCによって分析する。実施例1の化合物の溶解度は14.7mg/ml(又は塩基当量換算で12.1mg/ml)である。同じ条件下、3−[(3−{[4−(4−モルホリニルメチル)−1H−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1H−インドール−5−イル)-メチル]−1,3−チアゾリジン−2,4−ジオンの塩酸塩(Z異性体)の溶解度は4.3mg/ml(又は塩基当量換算で4mg/ml)である。
実施例1の生成物の一定の表面積溶解動力学(又は固有の溶解動力学)を、μDiss溶解装置及び0.075cm2のペレット(100rpmの撹拌速度で、90barで2分間の圧縮によって調製した)を使用して、周囲温度にてpH2(0.01N HCl 10mL)で決定した。実施例1の生成物は、23μg.s-1.cm-2+/−11%の動力学で溶解する。比較として、対応する塩酸塩の溶解動力学は1.6μg.s-1.cm-2である。そのため、メタンスルホン酸塩は、対応する塩酸塩よりも約14倍速く溶解する。
各々以下を含有する1000錠
用量5mgの3−[3−{[4−(4−モルホリニルメチル)−1H−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1H−インドール−5−イル)メチル]−1,3−チアゾリジン−2,4−ジオンメタンスルホン酸塩(Z異性体)(実施例1)
・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・5g
小麦デンプン・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・20g
トウモロコシデンプン・・・・・・・・・・・・・・・・・・・・・・・・・・・20g
乳糖・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・30g
ステアリン酸マグネシウム・・・・・・・・・・・・・・・・・・・・・・・・・・2g
シリカ・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・1g
ヒドロキシプロピルセルロース・・・・・・・・・・・・・・・・・・・・・・・・2g
Claims (14)
- 式(II):
[式中、表記×は、二重結合がZ又はE配置であることを意味する]
で表される、3−[(3−{[4−(4−モルホリニルメチル)−1H−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1H−インドール−5−イル)メチル]−1,3−チアゾリジン−2,4−ジオンメタンスルホン酸塩。 - 3−[(3−{[4−(4−モルホリニルメチル)−1H−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1H−インドール−5−イル)-メチル]−1,3−チアゾリジン−2,4−ジオンメタンスルホン酸塩のZ異性体である、請求項1に記載の化合物。
- ブラッグ角2θ(°±0.2を単位として表される)12.86;15.13;15.50;17.70;18.25;18.71;20.11;21.46;21.67;21.89;22.29;22.58;24.57;25.82;26.33によるそのX線粉末回折図によって特徴付けられる、請求項1又は2に記載の化合物。
- 以下の結晶パラメーターを同定することを可能にする、透過モードのPanalytical Xpert-Pro MPD回折計(銅対陰極)にて3〜55°の角度範囲(2θ単位)、0.017°のステップ及びステップ当たり35.5秒で実施された粉末回折図から開始して得られた以下のパラメーターによって特徴付けられる、請求項1又は2に記載の化合物:
単位格子パラメーター:a=15.0958(5)Å、b=18.4586(6)Å、c=8.8269(2)Å、β=94.074(1)°、γ=90°
空間群:C1c1(9)
単位格子の体積:V単位格子=2453.37600Å3。 - 3−[(3−{[4−(4−モルホリニルメチル)−1H−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1H−インドール−5−イル)-メチル]−1,3−チアゾリジン−2,4−ジオンを出発物質として使用し、溶媒/水の2成分系に溶解し、それに1〜2モル当量のメタンスルホン酸を加え、メタンスルホン酸塩が析出するまで撹拌し、それを濾別することを特徴とする、請求項1に記載の式(II)の化合物を得るためのプロセス。
- 3−[(3−{[4−(4−モルホリニルメチル)−1H−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1H−インドール−5−イル)-メチル]−1,3−チアゾリジン−2,4−ジオン塩酸塩を出発物質として使用し、溶媒/水の2成分系に溶解し、塩基を加えることによってそのpHを8にし、形成された塩を濾過によって除去し、次いで、濾液を加熱してメタンスルホン酸を加え、そして媒体を撹拌してメタンスルホン酸塩が析出するまで冷却し、それを濾別することを特徴とする、請求項1に記載の式(II)の化合物を得るためのプロセス。
- 請求項1〜4の一項に記載の式(II)の化合物を1つ以上の薬学的に許容し得る賦形剤と組み合わせて含む、医薬組成物。
- 式(II)の化合物が3−[(3−{[4−(4−モルホリニルメチル)−1H−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1H−インドール−5−イル)メチル]−1,3−チアゾリジン−2,4−ジオンメタンスルホン酸塩のZ異性体であることを特徴とする、請求項7に記載の医薬組成物。
- 結腸、乳房、肝臓、腎臓、脳及び食道の癌、悪性黒色腫、骨髄腫、卵巣癌、非小細胞肺癌、小細胞肺癌、前立腺及び膵臓の癌、又は肉腫の処置における使用のための医薬の製造における使用のための、請求項7又は8に記載の医薬組成物。
- 請求項1〜4のいずれか一項に記載の式(II)の化合物と遺伝毒性物質、細胞分裂毒、代謝拮抗物質、プロテアソーム阻害剤及びキナーゼ阻害剤から選択される抗癌剤との組み合わせ。
- 式(II)の化合物が3−[(3−{[4−(4−モルホリニルメチル)−1H−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1H−インドール−5−イル)メチル]−1,3−チアゾリジン−2,4−ジオンメタンスルホン酸塩のZ異性体であることを特徴とする、請求項10に記載の組み合わせ。
- 癌の処置における使用のための医薬の製造における、請求項10又は11に記載の組み合わせの使用。
- 癌の処置において放射線療法と組み合わせた、請求項1〜4のいずれか一項に記載の式(II)の化合物の使用。
- 式(II)の化合物が3−[(3−{[4−(4−モルホリニルメチル)−1H−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1H−インドール−5−イル)メチル]−1,3−チアゾリジン−2,4−ジオンメタンスルホン酸塩のZ異性体であることを特徴とする、請求項13に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1356870A FR3008411B1 (fr) | 2013-07-12 | 2013-07-12 | Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent |
FR13/56870 | 2013-07-12 | ||
PCT/FR2014/051783 WO2015004395A1 (fr) | 2013-07-12 | 2014-07-11 | Nouveau sel de la 3-[(3-{[4-(4-morpholinylméthyl)-1h-pyrrol-2-yl]méthylène}-2-oxo-2,3-dihydro-1h-indol-5-yl)méthyl]-1,3-thiazolidine-2,4-dione, sa préparation, et les formulations qui le contiennent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016523953A true JP2016523953A (ja) | 2016-08-12 |
JP6532459B2 JP6532459B2 (ja) | 2019-06-19 |
Family
ID=50424327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016524879A Expired - Fee Related JP6532459B2 (ja) | 2013-07-12 | 2014-07-11 | 3−[(3−{[4−(4−モルホリニルメチル)−1h−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1h−インドール−5−イル)メチル]−1,3−チアゾリジン−2,4−ジオンの新規塩、その調製及びそれを含有する製剤 |
Country Status (47)
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10245270B2 (en) * | 2013-07-12 | 2019-04-02 | Les Laboratoires Servier | Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it |
FR3039401B1 (fr) | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004511541A (ja) * | 2000-10-17 | 2004-04-15 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ活性を有する経口活性塩 |
JP2004522776A (ja) * | 2001-02-15 | 2004-07-29 | スージェン・インコーポレーテッド | 蛋白質キナーゼ阻害剤としての3−(4−アミドピロール−2−イルメチリデン)−2−インドリノン誘導体 |
JP2011037848A (ja) * | 2009-08-04 | 2011-02-24 | Lab Servier | 新規なジヒドロインドロン化合物、それらの調製方法及びそれらを含む薬学的組成物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE369359T1 (de) * | 2000-02-15 | 2007-08-15 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
CA2470480C (en) * | 2001-12-27 | 2010-12-14 | Theravance, Inc. | Indolinone derivatives useful as protein kinase inhibitors |
AU2004284084A1 (en) * | 2003-10-24 | 2005-05-06 | Schering Aktiengesellschaft | Indolinone derivatives and their use in treating disease-states such as cancer |
CN101365439B (zh) | 2005-12-05 | 2012-12-26 | 克塞诺波特公司 | 左旋多巴前体药物甲磺酸盐、其组合物及其用途 |
-
2013
- 2013-07-12 FR FR1356870A patent/FR3008411B1/fr active Active
-
2014
- 2014-06-26 UY UY0001035629A patent/UY35629A/es unknown
- 2014-06-29 JO JOP/2014/0205A patent/JO3292B1/ar active
- 2014-07-11 TN TN2015000566A patent/TN2015000566A1/fr unknown
- 2014-07-11 KR KR1020167003298A patent/KR20160030399A/ko active Application Filing
- 2014-07-11 NZ NZ715841A patent/NZ715841A/en not_active IP Right Cessation
- 2014-07-11 AU AU2014289059A patent/AU2014289059B2/en not_active Ceased
- 2014-07-11 CN CN201480038854.7A patent/CN105377843B/zh not_active Expired - Fee Related
- 2014-07-11 TW TW103124019A patent/TWI554510B/zh not_active IP Right Cessation
- 2014-07-11 PL PL14758600T patent/PL3019497T3/pl unknown
- 2014-07-11 JP JP2016524879A patent/JP6532459B2/ja not_active Expired - Fee Related
- 2014-07-11 PE PE2015002679A patent/PE20160079A1/es unknown
- 2014-07-11 EP EP14758600.2A patent/EP3019497B1/fr active Active
- 2014-07-11 MA MA38759A patent/MA38759B1/fr unknown
- 2014-07-11 ME MEP-2017-149A patent/ME02735B/me unknown
- 2014-07-11 DK DK14758600.2T patent/DK3019497T3/en active
- 2014-07-11 TW TW105105577A patent/TW201630906A/zh unknown
- 2014-07-11 AR ARP140102566A patent/AR096882A1/es unknown
- 2014-07-11 SI SI201430246A patent/SI3019497T1/sl unknown
- 2014-07-11 UA UAA201600944A patent/UA114041C2/uk unknown
- 2014-07-11 CA CA2916380A patent/CA2916380C/fr not_active Expired - Fee Related
- 2014-07-11 HU HUE14758600A patent/HUE032568T2/hu unknown
- 2014-07-11 US US14/904,260 patent/US9925195B2/en not_active Expired - Fee Related
- 2014-07-11 RU RU2016104642A patent/RU2680826C9/ru not_active IP Right Cessation
- 2014-07-11 KR KR1020187006643A patent/KR20180028554A/ko not_active Application Discontinuation
- 2014-07-11 AP AP2016008976A patent/AP2016008976A0/xx unknown
- 2014-07-11 RS RS20170461A patent/RS55945B1/sr unknown
- 2014-07-11 LT LTEP14758600.2T patent/LT3019497T/lt unknown
- 2014-07-11 MX MX2016000332A patent/MX360291B/es active IP Right Grant
- 2014-07-11 PT PT147586002T patent/PT3019497T/pt unknown
- 2014-07-11 MD MDA20160003A patent/MD4507C1/ro not_active IP Right Cessation
- 2014-07-11 GE GEAP201414051A patent/GEP201706712B/en unknown
- 2014-07-11 ES ES14758600.2T patent/ES2632570T3/es active Active
- 2014-07-11 MY MYPI2016700018A patent/MY183197A/en unknown
- 2014-07-11 EA EA201600101A patent/EA031526B1/ru not_active IP Right Cessation
- 2014-07-11 WO PCT/FR2014/051783 patent/WO2015004395A1/fr active Application Filing
- 2014-07-11 SG SG11201510570YA patent/SG11201510570YA/en unknown
-
2016
- 2016-01-04 PH PH12016500017A patent/PH12016500017B1/en unknown
- 2016-01-06 CL CL2016000013A patent/CL2016000013A1/es unknown
- 2016-01-07 DO DO2016000005A patent/DOP2016000005A/es unknown
- 2016-01-07 CR CR20160012A patent/CR20160012A/es unknown
- 2016-01-10 IL IL243526A patent/IL243526B/en not_active IP Right Cessation
- 2016-01-11 GT GT201600004A patent/GT201600004A/es unknown
- 2016-01-11 NI NI201600009A patent/NI201600009A/es unknown
- 2016-01-12 CU CUP2016000005A patent/CU20160005A7/es unknown
- 2016-01-12 SA SA516370388A patent/SA516370388B1/ar unknown
- 2016-08-30 HK HK16110306.0A patent/HK1222172A1/zh unknown
- 2016-09-13 HK HK16110825.2A patent/HK1222655A1/zh not_active IP Right Cessation
-
2017
- 2017-07-04 CY CY20171100714T patent/CY1119259T1/el unknown
- 2017-07-11 HR HRP20171060TT patent/HRP20171060T1/hr unknown
-
2018
- 2018-02-14 US US15/896,273 patent/US20180207171A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004511541A (ja) * | 2000-10-17 | 2004-04-15 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ活性を有する経口活性塩 |
JP2004522776A (ja) * | 2001-02-15 | 2004-07-29 | スージェン・インコーポレーテッド | 蛋白質キナーゼ阻害剤としての3−(4−アミドピロール−2−イルメチリデン)−2−インドリノン誘導体 |
JP2011037848A (ja) * | 2009-08-04 | 2011-02-24 | Lab Servier | 新規なジヒドロインドロン化合物、それらの調製方法及びそれらを含む薬学的組成物 |
Non-Patent Citations (3)
Title |
---|
STAHLY,P.: "医薬品の塩選択,結晶多形のスクリーニングの重要性について", 薬剤学, vol. 66, no. 6, JPN6015024142, 2006, pages 435 - 439, ISSN: 0003476240 * |
小嶌隆史: "医薬品開発における結晶性選択の効率化を目指して", 薬剤学, vol. 68, no. 5, JPN6009053757, 1 September 2008 (2008-09-01), pages 344 - 349, ISSN: 0003476241 * |
芦澤一英: "塩・結晶形の最適化と結晶化技術", PHARM TECH JAPAN, vol. 18, no. 10, JPN6013060608, 2002, pages 81 - 96, ISSN: 0003476239 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7383652B2 (ja) | B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 | |
TWI585088B (zh) | 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 | |
CN110036007B (zh) | 吡啶化合物 | |
TWI426072B (zh) | 4-胺基-5-氟-3-〔5-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基〕喹啉-2(1h)-酮乳酸鹽之結晶型及兩種溶合物型 | |
JP7432590B2 (ja) | 選択的cdk9阻害剤としての酒石酸塩及びその結晶形 | |
JP5758399B2 (ja) | 化合物、その一定の新形態、その医薬組成物ならびに製剤化および使用の方法 | |
WO2011023146A1 (en) | Imatinib mesylate polymorphs generated by crystallization in aqueous inorganic salt solutions | |
JP2019518776A (ja) | Egfr阻害剤としてのアニリンピリミジン化合物の結晶 | |
JP6532459B2 (ja) | 3−[(3−{[4−(4−モルホリニルメチル)−1h−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1h−インドール−5−イル)メチル]−1,3−チアゾリジン−2,4−ジオンの新規塩、その調製及びそれを含有する製剤 | |
JP7299350B2 (ja) | Rip-1キナーゼ阻害剤としての二環式化合物およびその使用 | |
WO2016187028A1 (en) | Heteroaryl compounds, synthesis thereof, and intermediates thereto | |
US10245270B2 (en) | Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it | |
WO2024048615A1 (ja) | キノキサリン誘導体の製造方法 | |
TWI344462B (en) | Indole derivatives having an apoptosis-inducing effect | |
TW201008936A (en) | Crystalline forms of thiazolidinedione compound and its manufacturing method | |
TW201211036A (en) | Useful salts of indazole derivative | |
CN109678813A (zh) | 吲哚胺-2,3-双加氧酶抑制剂盐及其制备方法 | |
OA17666A (fr) | Nouveau sel de la 3-[(3-{[4-(4Morpholinylméthyl)-1H-Pyrrol-2-YL]Methylène}-2Oxo-2,3-Dihydro-1H-Indol-5-YL)Méthyl]-1,3-Thiazolidine-2,4-Dione, sa préparation, et les formulations qui le contiennent. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161215 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170411 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170926 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180115 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180124 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20180302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181031 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190521 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6532459 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |